on the way to $1, page-31

Thanks for your thoughts and sharing your experience.

One thing I will disagree with you on is that the Prospectus does not say that one of the biomarkers was contaminated in transport, it said that it may have been. It is disingenuous to claim otherwise. Sure that may be your opinion but we must go off the prospectus and information released to the market.

Page 29 of the prospectus:

"Study 5 (2015-16)
• Large case/control study of 543 patients (yet unpublished). • Performance of 3 lead biomarkers with six additional candidate markers. • Applied in a real-time, clinical setting, using commercially available assays. • Raw data showed results were inconclusive in respect of the proposed 3 biomarker ColoSTAT™ panel, as a result of the aberrant measured performance of one of the lead biomarkers. This result may be related to the stability or performance properties of the specific batch of commercially sourced assay kit, further research and development work is required (refer to proposed Study 6 and Study 7 below). • In-house development of antibodies and antigen reagents expected to reduce the risks of unreliable supply and test performance variability associated with commercially available assay kits. This is to be completed in preparation for Study 6. • Results were encouraging in respect of the potential for a new combination of the assessed biomarkers to form a diagnostic screening test for early stage disease."


If the new biomarker proves a success then the plan will continue, if it doesn't this will not be pretty. High risk IMO.

May still have a punt. Will see.

Thanks again for sharing your thoughts, will keep watching.